THE DAY, IN CONTEXTPolaris InsightsAn AI-powered comprehensive news portal

POLARIS INSIGHTS

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
View original story →

NVO NVO AZN-GB MRK ABBV NVS XPH LLY IHE IYH XBI EDEN GILD AMGN BIIB watch now VIDEO 1:03 01:03 Novo shares sink as weight-loss drug giant unveils 2030 strategy Squawk Box Europe Novo shares plummeted on Monday after the company's

Read the original report for the complete account of this story.

More from the Markets desk

More from Markets · Back to Polaris Insights